安科生物(300009) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥628,754,570.48, a decrease of 4.17% compared to ¥656,092,096.17 in the same period last year[5] - Net profit attributable to shareholders was ¥209,002,473.85, down 4.02% from ¥217,749,931.36 year-on-year[5] - Basic earnings per share decreased by 3.77% to ¥0.1250 from ¥0.1299 in the same period last year[5] - Total operating revenue for the current period is CNY 628,754,570.48, a decrease of 4.9% from CNY 656,092,096.17 in the previous period[21] - Net profit for the current period is CNY 213,314,968.37, a decrease of 3.0% compared to CNY 221,942,342.95 in the previous period[23] - Earnings per share (EPS) for the current period is CNY 0.12, unchanged from the previous period[23] Cash Flow - The net cash flow from operating activities increased by 26.17% to ¥195,228,976.90, compared to ¥154,730,370.05 in the previous year[5] - The net cash flow from operating activities for the current period is ¥195,228,976.90, an increase of 26.2% compared to ¥154,730,370.05 in the previous period[24] - Cash inflow from investment activities totaled ¥984,226,816.56, up from ¥905,331,713.15 in the previous period, representing an increase of 8.7%[24] - The net cash flow from investment activities is -¥24,047,872.85, an improvement from -¥96,743,186.35 in the previous period[24] - Cash outflow from financing activities is ¥206,540,716.57, significantly higher than ¥2,197,333.40 in the previous period[25] - The net increase in cash and cash equivalents is -¥37,829,661.85, compared to an increase of ¥55,803,414.51 in the previous period[25] - The ending balance of cash and cash equivalents is ¥260,775,273.12, down from ¥314,587,364.25 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,104,225,659.62, a decrease of 0.61% from ¥5,135,349,855.72 at the end of the previous year[5] - Total liabilities are CNY 843,466,279.55, an increase from CNY 835,412,154.71 in the previous period[20] - Non-current assets total CNY 3,012,443,453.75, up from CNY 2,860,254,070.71[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 67,145[12] - The largest shareholder, Song Lihua, holds 26.56% of the shares, totaling 444,278,710 shares[12] - The second-largest shareholder, Song Liming, holds 6.87% of the shares, totaling 114,889,420 shares[12] - The top 10 shareholders collectively hold significant stakes, with the largest three shareholders accounting for 35.10% of total shares[12] - The company has no preferred shareholders as indicated in the report[13] - The report indicates that there are no changes in the participation of the top 10 shareholders in margin financing and securities lending[12] - The report does not indicate any known relationships or concerted actions among other shareholders[12] Investment and Expenses - The company reported a significant increase in financial expenses, rising 680.31% to ¥2,420,118.23 due to higher foreign exchange losses[10] - Other income increased by 56.02% to ¥11,470,548.23, primarily due to higher government subsidies received[10] - Investment income surged by 387.09% to ¥6,347,951.75, attributed to gains from equity disposals by subsidiaries[10] - Research and development expenses for the current period are CNY 33,910,492.09, down from CNY 37,176,848.42[23] Current Assets - As of March 31, 2025, the company's total current assets amounted to CNY 2,091,782,205.87, down from CNY 2,275,095,785.01 at the beginning of the period, representing a decrease of approximately 8.06%[17] - The company's cash and cash equivalents decreased from CNY 299,180,346.54 to CNY 261,350,684.69, a decline of about 12.67%[17] - Trade receivables increased from CNY 442,317,739.96 to CNY 464,034,121.69, reflecting an increase of approximately 4.00%[17] - The company’s inventory decreased from CNY 297,295,906.07 to CNY 289,142,288.85, a reduction of about 2.45%[17] - The company’s total non-current assets included debt investments of CNY 240,144,388.88, slightly up from CNY 238,516,888.88[17] - The company’s receivables financing increased from CNY 50,037,121.80 to CNY 79,462,206.75, an increase of approximately 58.73%[17] - The company’s other receivables rose from CNY 30,403,158.68 to CNY 39,071,132.23, marking an increase of about 28.49%[17] Other Information - The company approved an investment through its wholly-owned subsidiary in VISEN Pharmaceuticals, which went public on March 21, 2025[16] - The company completed the registration of its third phase of restricted stock incentive plan, with a total of 14,664,760 shares[14] - The company distributed cash dividends totaling CNY 166,836,625.20 (including tax) for the first three quarters of 2024[15] - Other comprehensive income after tax is CNY -44,881,085.50, reflecting a decrease in fair value of equity investments[23]